Actively Recruiting
Study of Saruparib AZD5305 Plus Camizestrant Compared to CDK46 Inhibitors Plus Endocrine Therapy in BRCA or PALB2 Mutated HR-Positive, HER2-Negative Advanced Breast Cancer
Led by AstraZeneca · Updated on 2026-10-30
788
Participants Needed
306
Research Sites
106 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness of saruparib AZD5305 combined with camizestrant compared to physicians choice of CDK46 inhibitors plus endocrine therapy in patients with BRCA1, BRCA2, or PALB2 mutated, hormone receptor-positive, HER2-negative advanced breast cancer. This phase III study aims to determine which treatment better controls disease progression in this specific patient population. Participants will be randomly assigned to one of four treatment groups saruparib plus camizestrant physicians choice CDK46 inhibitor plus endocrine therapy physicians choice CDK46 inhibitor plus camizestrant or saruparib plus physicians choice endocrine therapy. Treatments are given orally or by injection as appropriate and will continue until the disease progresses, unacceptable side effects occur, or participants choose to stop treatment. During the study, participants will have regular assessments to evaluate disease progression, survival, response to treatment, and quality of life. Researchers will monitor drug levels in the blood and collect tissue samples to support diagnostic development. The study may last up to several years, with ongoing safety and efficacy evaluations to understand the impact of these treatments on advanced breast cancer.
CONDITIONS
Brief Title
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here